In brief: Meditech, Psivida, Regenera, Mesoblast
Wednesday, 24 August, 2005
Cancer biopharma Meditech Research (ASX:MTR) has been offered a AUD$2.98 million AusIndustry Commercial Ready Grant over the next three years towards the development and commercialisation of its lead anti-cancer product HyCAMP, which is in Phase II clinical testing.
Meanwhile, Robert Stewart has taken over as Meditech's chairman. Prof Richard Fox will remain as a non-executive director and will continue to advise the company on clinical development and medical issues.
Perth-based nanotech Psivida (ASX:PSD) has raised US$4.2 million before costs via the private placement of 650,000 on American Depository Receipts to predominantly US investors at US$6.50 each. Each ADR represents 10 ordinary shares.
Perth's Regenera (ASX:RGA) has received its first licensing payment of AUD$1.3 million from Alcon Manufacturing in accordance with an exclusive global license granted by Regenera to Alcon in April 2005. The license involves a steroid product that is used during ocular surgery. Adult stem cell company Mesoblast (ASX:MSB) has entered into an agreement with an unnamed medical device company which will provide carrier materials for use in Mesoblast's preclinical trials.
Scientists complete final chromosome in synthetic yeast genome
The synthetic chromosome includes features that enable researchers to generate genetic diversity...
Self-destructing vaccine protects against TB in monkeys
A self-destructing vaccine administered intravenously provides additional safety and protection...
New drug to prevent migraine claimed to work straight away
People taking atogepant showed improvement on assessments of how much migraine impaired their...
